CNS Pharmaceuticals, Inc. Interest Expense
CNS Pharmaceuticals, Inc. (CNSP) reported Interest Expense of $6.63 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-05-15
- CNS Pharmaceuticals, Inc. interest expense for the quarter ending 2024-03-31 was $6.63K, a 21.87% increase year-over-year.
- CNS Pharmaceuticals, Inc. interest expense for the quarter ending 2023-12-31 was $2.88K, a 24.61% increase year-over-year.
- CNS Pharmaceuticals, Inc. interest expense for the quarter ending 2023-09-30 was $1.84K, a 241.64% increase year-over-year.
- CNS Pharmaceuticals, Inc. interest expense for the quarter ending 2023-06-30 was $3.65K, a 126.57% increase year-over-year.
- CNS Pharmaceuticals, Inc. interest expense for fiscal 2023 was $13.80K, a 96.46% increase from fiscal 2022.
- CNS Pharmaceuticals, Inc. interest expense for fiscal 2022 was $7.03K, a 24.32% decline from fiscal 2021.
- CNS Pharmaceuticals, Inc. interest expense for fiscal 2021 was $9.29K, a 184.47% increase from fiscal 2020.
- CNS Pharmaceuticals, Inc. interest expense for fiscal 2020 was $3.26K, a 87.52% decline from fiscal 2019.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $6.63K 10-Q · filed 2024-05-15 | $9.51K derived: sum of 2 quarters · filed 2024-05-15 | $11.34K derived: sum of 3 quarters · filed 2024-05-15 | $14.99K derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-12-31 | $2.88K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $4.72K derived: sum of 2 quarters · filed 2024-04-01 | $8.37K derived: sum of 3 quarters · filed 2024-04-01 | $13.80K 10-K · filed 2024-04-01 |
| 2023-09-30 | $1.84K 10-Q · filed 2023-11-14 | $5.49K derived: sum of 2 quarters · filed 2023-11-14 | $10.92K 10-Q · filed 2023-11-14 | $13.24K derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-06-30 | $3.65K 10-Q · filed 2023-08-14 | $9.09K 10-Q · filed 2023-08-14 | $11.40K derived: sum of 3 quarters · filed 2024-05-15 | $11.94K derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-03-31 | $5.44K 10-Q · filed 2024-05-15 | $7.75K derived: sum of 2 quarters · filed 2024-05-15 | $8.29K derived: sum of 3 quarters · filed 2024-05-15 | $9.90K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $2.31K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $2.85K derived: sum of 2 quarters · filed 2024-04-01 | $4.46K derived: sum of 3 quarters · filed 2024-04-01 | $7.03K 10-K · filed 2024-04-01 |
| 2022-09-30 | $538.00 10-Q · filed 2023-11-14 | $2.15K derived: sum of 2 quarters · filed 2023-11-14 | $4.71K 10-Q · filed 2023-11-14 | $6.95K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $1.61K 10-Q · filed 2023-08-14 | $4.18K 10-Q · filed 2023-08-14 | $6.42K derived: sum of 3 quarters · filed 2023-08-14 | $7.36K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $2.57K 10-Q · filed 2023-05-15 | $4.80K derived: sum of 2 quarters · filed 2023-05-15 | $5.75K derived: sum of 3 quarters · filed 2023-05-15 | $8.10K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $2.24K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $3.19K derived: sum of 2 quarters · filed 2023-03-31 | $5.54K derived: sum of 3 quarters · filed 2023-03-31 | $9.29K 10-K · filed 2023-03-31 |
| 2021-09-30 | $947.00 10-Q · filed 2022-11-10 | $3.30K derived: sum of 2 quarters · filed 2022-11-10 | $7.05K 10-Q · filed 2022-11-10 | $10.31K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $2.35K 10-Q · filed 2022-08-12 | $6.10K 10-Q · filed 2022-08-12 | $9.36K derived: sum of 3 quarters · filed 2022-08-12 | $9.36K derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $3.75K 10-Q · filed 2022-05-13 | $7.01K derived: sum of 2 quarters · filed 2022-05-13 | $7.01K derived: sum of 3 quarters · filed 2022-05-13 | $7.01K derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $3.26K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $3.26K derived: sum of 2 quarters · filed 2022-03-03 | $3.26K derived: sum of 3 quarters · filed 2022-03-03 | $3.26K 10-K · filed 2022-03-03 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-12 | $0.00 derived: sum of 2 quarters · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 | $3.62K derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-13 | $0.00 10-Q · filed 2021-08-13 | $3.62K derived: sum of 3 quarters · filed 2021-08-13 | $11.18K derived: sum of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-13 | $3.62K derived: sum of 2 quarters · filed 2021-05-13 | $11.18K derived: sum of 3 quarters · filed 2021-05-13 | $18.66K derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $3.62K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $11.18K derived: sum of 2 quarters · filed 2021-02-12 | $18.66K derived: sum of 3 quarters · filed 2021-02-12 | $26.15K 10-K · filed 2021-02-12 |
| 2019-09-30 | $7.56K 10-Q · filed 2020-11-12 | $15.04K derived: sum of 2 quarters · filed 2020-11-12 | $22.54K 10-Q · filed 2020-11-12 | $33.17K derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $7.48K 10-Q · filed 2020-08-10 | $14.97K 10-Q · filed 2020-08-10 | $25.61K derived: sum of 3 quarters · filed 2020-08-10 | $36.24K derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $7.49K 10-Q · filed 2020-05-15 | $18.13K derived: sum of 2 quarters · filed 2020-05-15 | $28.76K derived: sum of 3 quarters · filed 2020-05-15 | |
| 2018-12-31 | $10.63K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $21.26K derived: sum of 2 quarters · filed 2020-03-12 | $28.61K 10-K · filed 2020-03-12 | |
| 2018-09-30 | $10.63K 10-Q · filed 2019-12-20 | $17.98K 10-Q · filed 2019-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |